JAK2 and clear cell renal carcinoma: For example, constitutive activation of JAK2/STAT3 signaling has been reported to contribute to tumor growth and metastasis in clear cell renal cell carcinoma (Deng et al. 2023), gallbladder cancer (Yang et al. 2024), and other malignancies, highlighting its role as a potential therapeutic target.